New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
05:26 EDTAMPEAmpio announces active IND for Optina for treatment of DME
Ampio Pharmaceuticals announced that the FDA has accepted the company's IND for Optina for the treatment of Diabetic Macular Edema, or DME. Ampio plans to commence enrollment in a clinical trial in Q1. The FDA granted Optina 505 b 2 status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
09:14 EDTAMPEAmpio to host business news update conference call
Subscribe for More Information
April 20, 2015
08:49 EDTAMPEAmpio announces STRIDE study AP008 did not reach its primary endpoint
Ampio Pharmaceuticals announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion. This pain reduction with Ampion was consistent across all sites and with our previously reported studies Ampion is safe and well tolerated. Ampio Pharmaceuticals launched the Phase III program for AmpionTM to treat pain due to osteoarthritis, OA, of the knee. Each patient received three 4ml intra-articular injections of Ampion, or the saline placebo, one at baseline, the second at two weeks and the third at four weeks. In OA, saline is known to be a partial therapeutic and not a true placebo, but has been the control used in all published OA drug trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use